Huma Y Attari, MD
Psychiatry · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 14 years
- State University of New York at Buffalo School of Medicine, 2012
Offices
2 locations · Regents of the Univ of CA · Regents of the University of California
Looking this up.
Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Attari’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C14363 · Cancelled
Licence status: Cancelled · since 1952 · New York University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$20,635
Medicare paid this office $20,635 for 102 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Psychiatric diagnostic evaluation with medical services | 45 | $5,889 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $5,849 | $60 |
| Return visit (30+ min) | 14 | $4,510 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,175 | $90 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $255 | $13 |
Who their Medicare patients are
102 Original Medicare patients in 2024. Average age 64 · Under 65 35% · Women 51% · Also on Medicaid 67% · Health risk score 2.23. Sicker patients than 9 in 10 peers; the typical psychiatry clinician is at 1.35.
Conditions among them: High blood pressure 71% · Depression 66% · Diabetes 40% · Heart failure 26% · Dementia 26% · Chronic kidney disease 25% · COPD 23% · Coronary heart disease 18% · Atrial fibrillation 18% · Stroke 15% · Cancer 14%.
The office billed $105,082, Medicare allowed $27,322 and paid $20,635; for 253 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 102 | 253 | 64 | 2.23 | $105,082 | $20,635 |
| 2023 | 87 | 233 | 64 | 2.01 | $94,649 | $21,025 |
| 2022 | 93 | 216 | 65 | 1.92 | $88,807 | $19,879 |
| 2021 | 116 | 272 | 61 | 2.09 | $92,621 | $23,043 |
| 2020 | 187 | 405 | 60 | 1.90 | $131,085 | $29,183 |
| 2019 | 216 | 433 | 59 | 2.04 | $136,576 | $30,020 |
| 2018 | 206 | 409 | 60 | 2.19 | $135,688 | $30,002 |
| 2017 | 101 | 220 | 62 | 2.21 | $67,384 | $16,033 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $5,861 | $66 |
| Psychiatric diagnostic evaluation with medical services | 30 | $4,276 | $143 |
| Return visit (30+ min) | 11 | $2,941 | $109 |
| Psychiatric diagnostic evaluation with medical services | 11 | $1,809 | $164 |
| Short return visit (20+ min) | 12 | $1,575 | $68 |
2022: 5 services
| Psychiatric diagnostic evaluation with medical services | 34 | $5,196 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,924 | $57 |
| Short return visit (20+ min) | 18 | $2,575 | $68 |
| Psychiatric diagnostic evaluation with medical services | 13 | $2,313 | $165 |
| Return visit (30+ min) | 11 | $1,971 | $104 |
2021: 5 services
| Psychiatric diagnostic evaluation with medical services | 29 | $4,702 | $147 |
| Return visit (30+ min) | 19 | $3,759 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,108 | $60 |
| Psychiatric diagnostic evaluation with medical services | 14 | $2,204 | $157 |
| Short return visit (20+ min) | 16 | $1,637 | $63 |
2020: 7 services
| Psychiatric diagnostic evaluation with medical services | 67 | $8,410 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $4,307 | $61 |
| Short return visit (20+ min) | 20 | $3,486 | $60 |
| Return visit (30+ min) | 22 | $3,325 | $67 |
| Psychiatric diagnostic evaluation with medical services | 18 | $2,418 | $134 |
| Short return visit (20+ min) | 30 | $1,807 | $41 |
| Emergency department visit with low level of medical decision making | 25 | $1,802 | $53 |
2019: 6 services
| Psychiatric diagnostic evaluation with medical services | 82 | $9,575 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $5,683 | $59 |
| Return visit (30+ min) | 38 | $4,882 | $64 |
| Short return visit (20+ min) | 26 | $3,328 | $54 |
| Short return visit (20+ min) | 43 | $3,162 | $42 |
| Psychiatric diagnostic evaluation with medical services | 19 | $2,276 | $120 |
2018: 6 services
| Psychiatric diagnostic evaluation with medical services | 81 | $9,940 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $4,979 | $59 |
| Short return visit (20+ min) | 22 | $3,974 | $58 |
| Psychiatric diagnostic evaluation with medical services | 29 | $3,330 | $115 |
| Emergency department visit with low level of medical decision making | 21 | $1,784 | $50 |
| Short return visit (20+ min) | 15 | $828 | $39 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $5,627 | $59 |
| Psychiatric diagnostic evaluation with medical services | 35 | $4,934 | $115 |
| Psychiatric diagnostic evaluation with medical services | 19 | $1,904 | $100 |
Medicaid work
$2,152 in 2024
Medicaid paid $2,152 for 14 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Psychiatric diagnostic evaluation with medical services | 14 | $2,152 |
| 2024 | 14 | 1 | 13 | $2,152 |
| 2022 | 20 | 1 | 20 | $0 |
See the largest Medicaid services in earlier years
2022
| Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes | 20 | $0 |
Drugs they prescribed that Part D paid
$24,803
Pharmacies billed $24,803 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 232) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
199 generic and 33 brand-name prescriptions · $24,803 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bupropion Xl | 21 | $6,185 | $295 |
| Ritalin La | 12 | $6,177 | $515 |
| Trazodone | 17 | $713 | $42 |
| Clonazepam | 33 | $439 | $13 |
| Fluoxetine | 14 | $135 | $10 |
See all 8 drugs
| Bupropion Xl | 21 | $6,185 | $295 |
| Ritalin La | 12 | $6,177 | $515 |
| Trazodone | 17 | $713 | $42 |
| Clonazepam | 33 | $439 | $13 |
| Fluoxetine | 14 | $135 | $10 |
| Quetiapine | 11 | $88 | $8 |
| Lamotrigine | 11 | $40 | $4 |
| Propranolol | 11 | $39 | $4 |
Year by year
| 2024 | 232 | 25 | 0% (0) | 14% | $24,803 |
| 2023 | 226 | 22 | 0% (0) | 11% | $25,203 |
| 2022 | 189 | 19 | 0% (0) | 15% | $24,907 |
| 2021 | 159 | 20 | 0% (0) | 17% | $26,119 |
| 2020 | 199 | 26 | 0% (0) | 11% | $17,785 |
| 2019 | 108 | 19 | 0% (0) | 10% | $9,093 |
| 2018 | 120 | 13 | 0% (0) | None | $4,739 |
| 2017 | 55 | 17 | 0% (0) | 0% | $739 |
| 2016 | 50 | None | 0% (0) | None | $2,679 |
| 2015 | 245 | 22 | 0% (0) | 16% | $13,691 |
| 2014 | 124 | 18 | 0% (0) | 15% | $5,682 |
| 2013 | 19 | None | 0% (0) | None | $790 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Bupropion Xl | 25 | $7,525 | $301 |
| Trazodone | 19 | $828 | $44 |
| Clonazepam | 28 | $659 | $24 |
| Quetiapine | 15 | $457 | $30 |
| Methylphenidate La | 11 | $365 | $33 |
| Fluoxetine | 17 | $173 | $10 |
| Propranolol | 12 | $83 | $7 |
| Lamotrigine | 12 | $53 | $4 |
2022: 6 drugs
| Bupropion Xl | 21 | $8,022 | $382 |
| Trazodone | 16 | $1,045 | $65 |
| Quetiapine | 14 | $244 | $17 |
| Fluoxetine | 17 | $155 | $9 |
| Lamotrigine | 12 | $43 | $4 |
| Clonazepam | 12 | $42 | $3 |
2021: 5 drugs
| Bupropion Xl | 21 | $4,920 | $234 |
| Trazodone | 12 | $912 | $76 |
| Fluoxetine | 16 | $176 | $11 |
| Propranolol | 13 | $148 | $11 |
| Clonazepam | 16 | $38 | $2 |
2020: 6 drugs
| Bupropion Xl | 20 | $3,523 | $176 |
| Trazodone | 16 | $1,084 | $68 |
| Propranolol | 14 | $241 | $17 |
| Fluoxetine | 13 | $109 | $8 |
| Sertraline | 13 | $58 | $4 |
| Clonazepam | 18 | $45 | $3 |
2019: 2 drugs
| Trazodone | 18 | $409 | $23 |
| Clonazepam | 16 | $89 | $6 |
2018: 3 drugs
| Trazodone | 24 | $81 | $3 |
| Clonazepam | 13 | $52 | $4 |
| Risperidone | 11 | $48 | $4 |
2016: 1 drug
| Divalproex Sodium Er | 11 | $1,712 | $156 |
2015: 8 drugs
| Divalproex Sodium Er | 26 | $3,885 | $149 |
| Olanzapine | 27 | $536 | $20 |
| Sertraline | 33 | $244 | $7 |
| Venlafaxine | 14 | $231 | $17 |
| Mirtazapine | 16 | $172 | $11 |
| Lithium Carbonate | 20 | $140 | $7 |
| Lorazepam | 15 | $78 | $5 |
| Clonazepam | 12 | $29 | $2 |
2014: 3 drugs
| Olanzapine | 19 | $1,708 | $90 |
| Sertraline | 18 | $175 | $10 |
| Mirtazapine | 12 | $164 | $14 |
Money from drug and device companies
$12 in 2022
A payment is not proof that care is biased.
| GlaxoSmithKline | Benlysta | $12 | 1 payment
|
See the published payment
| GlaxoSmithKline | Meals · 2022-12-19 | Benlysta | $12 |
Professional record
- NPI
- 1760740286
- Licence
- CA 14363California C14363: Cancelled
- Trained
- State University of New York at Buffalo School of Medicine, 2012 · 14 years ago
- Group
- Regents of the Univ of CA · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 3250 Vintage Oaks Ct, San Jose, CA, 95148
- NPI first listed
- 2012-05-03
- NPI last updated
- 2026-05-21
- NPI record certified
- 2026-05-21
This is when the NPI record was last certified, not a medical board exam.